Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics

References

• Abuasal, B.S., et al., 2012. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability. Lipids, 47 (5), 461–469.
   PubMed Web of Science ®Google Scholar
• Adams, J., 2003. The proteasome: structure, function, and role in the cell. Cancer treatment reviews, 29, 3–9.
   PubMed Web of Science ®Google Scholar
• Adams, J., 2004a. The development of proteasome inhibitors as anticancer drugs. Cancer cell, 5 (5), 417–421.
   PubMed Web of Science ®Google Scholar
• Adams, J., 2004b. The proteasome: a suitable antineoplastic target. Nature reviews. Cancer, 4 (5), 349–360.
   PubMed Web of Science ®Google Scholar
• Adams, J., et al., 1998. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorganic & medicinal chemistry letters, 8 (4), 333–338.
   PubMed Web of Science ®Google Scholar
• Adams, J. and Stein, R., 1996. Novel inhibitors of the proteasome and their therapeutic use in inflammation. In: Annual reports in medicinal chemistry. Vol. 31. New York, NY: Elsevier, 279–288.
   Google Scholar
• Aditya, N. and Ko, S., 2015. Solid lipid nanoparticles (SLNs): delivery vehicles for food bioactives. RSC advances, 5 (39), 30902–30911.
   Web of Science ®Google Scholar
• Agrawal, U., et al., 2014. Is nanotechnology a boon for oral drug delivery? Drug discovery today, 19 (10), 1530–1546.
   PubMed Web of Science ®Google Scholar
• Ahmed, K.S., et al., 2019. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. Journal of drug targeting, 27 (7), 742–761.
   PubMed Web of Science ®Google Scholar
• Anjum, R. and Lakshmi, P., 2009. A review on solid lipid nanoparticles; focus on excipients and formulation techniques. International journal of pharmacy and pharmaceutical sciences, 5(1), 90–93.
   Google Scholar
• Ashley, J.D., et al., 2014. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. Journal of medicinal chemistry, 57 (12), 5282–5292.
   PubMed Web of Science ®Google Scholar
• Bisso, S. and Leroux, J.-C., 2020. Nanopharmaceuticals: a focus on their clinical translatability. International journal of pharmaceutics, 578, 119098.
   PubMed Web of Science ®Google Scholar
• Bulbake, U., et al., 2017. Liposomal formulations in clinical use: an updated review. Pharmaceutics, 9 (4), 12.
   PubMed Web of Science ®Google Scholar
• Butu, A., et al., 2015. Liposomal nanodelivery system for proteasome inhibitor anticancer drug bortezomib. Farmacia, 63 (2), 224–229.
   Web of Science ®Google Scholar
• Chatterjee, B., et al., 2016. Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view. Drug delivery, 23 (9), 3639–3652.
   PubMed Web of Science ®Google Scholar
• Chenthamara, D., et al., 2019. Therapeutic efficacy of nanoparticles and routes of administration. Biomaterial research, 23 (1), 1–29.
   PubMedGoogle Scholar
• Cherniakov, I., Domb, A.J., and Hoffman, A., 2015. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert opinion on drug delivery, 12 (7), 1121–1133.
   PubMed Web of Science ®Google Scholar
• Date, A.A., et al., 2010. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine, 5 (10), 1595–1616.
   PubMed Web of Science ®Google Scholar
• De Jong, W.H. and Borm, P.J., 2008. Drug delivery and nanoparticles: applications and hazards. International journal of nanomedicine, 3 (2), 133–149.
   PubMed Web of Science ®Google Scholar
• Deshantri, A.K., et al., 2019. Development and characterization of liposomal formulation of bortezomib. International journal of pharmaceutics, 1, 100011.
   Web of Science ®Google Scholar
• Dick, L.R. and Fleming, P.E., 2010. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug discovery today, 15 (5–6), 243–249.
   PubMed Web of Science ®Google Scholar
• Doktorovova, S., Shegokar, R., and Souto, E. B., 2017. Role of excipients in formulation development and biocompatibility of lipid nanoparticles (SLNs/NLCs). In: Nanostructures for novel therapy. New York, NY: Elsevier, 811–843.
   Google Scholar
• Drummond, D.C., et al., 2008. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. Journal of pharmaceutical sciences, 97 (11), 4696–4740.
   PubMed Web of Science ®Google Scholar
• Fagerholm, U., Johansson, M., and Lennernäs, H., 1996. Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical research, 13 (9), 1336–1342.
   PubMed Web of Science ®Google Scholar
• Farokhzad, O.C. and Langer, R.J.A., 2009. Impact of nanotechnology on drug delivery. ACS nano, 3 (1), 16–20.
   PubMed Web of Science ®Google Scholar
• Gandolfi, S., et al., 2017. The proteasome and proteasome inhibitors in multiple myeloma. Cancer metastasis reviews, 36 (4), 561–584.
   PubMed Web of Science ®Google Scholar
• Ganesan, P., et al., 2018. Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases. International journal of nanomedicine, 13, 1569–1583.
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh, P. and Mohammadi-Samani, S., 2018. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Research in pharmaceutical sciences, 13 (4), 288–303.
   PubMed Web of Science ®Google Scholar
• Goldberg, A.L., 2012. Development of proteasome inhibitors as research tools and cancer drugs. New York, NY: Rockefeller University Press.
   Google Scholar
• Guri, A., Gülseren, I., and Corredig, M., 2013. Utilization of solid lipid nanoparticles for enhanced delivery of curcumin in cocultures of HT29-MTX and Caco-2 cells. Food & function, 4 (9), 1410–1419.
   PubMed Web of Science ®Google Scholar
• Gursoy, R.N. and Benita, S., 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine & pharmacotherapy, 58 (3), 173–182.
   PubMed Web of Science ®Google Scholar
• Hideshima, T., et al., 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer research, 61 (7), 3071–3076.
   PubMed Web of Science ®Google Scholar
• Hong, E.-P., et al., 2016. Formulation and evaluation of a self-microemulsifying drug delivery system containing bortezomib. Chemical & pharmaceutical bulletin, 64 (8), 1108–1117.
   PubMed Web of Science ®Google Scholar
• Ibrahim, W.M., AlOmrani, A.H., and Yassin, A.E.B., 2014. Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability. International journal nanomedicine, 9, 129.
   PubMed Web of Science ®Google Scholar
• Joshi, M.D., et al., 2017. In vitro evaluation of bortezomib encapsulated in cationic and C6-ceramide liposomes. Journal of pharmaceutical sciences and pharmacology, 3 (2), 146–154.
   Google Scholar
• Kaplan, G.S., et al., 2017. Proteasome inhibitors in cancer therapy: treatment regimen and peripheral neuropathy as a side effect. Free radical biology & medicine, 103, 1–13.
   PubMed Web of Science ®Google Scholar
• Khan, A.W., et al., 2012. Potentials and challenges in self-nanoemulsifying drug delivery systems. Expert opinion on drug delivery, 9 (10), 1305–1317.
   PubMed Web of Science ®Google Scholar
• Kohli, K., et al., 2010. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug discovery today, 15 (21–22), 958–965.
   PubMed Web of Science ®Google Scholar
• Korani, M., et al., 2019. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma. Nanomedicine: nanotechnology, biology and medicine, 20, 102013.
   PubMed Web of Science ®Google Scholar
• Kubiczkova, L., et al., 2014. Proteasome inhibitors–molecular basis and current perspectives in multiple myeloma. Journal of cellular and molecular medicine, 18 (6), 947–961.
   PubMed Web of Science ®Google Scholar
• Kumar, A., Sharma, S., and Kamble, R., 2010. Self emulsifying drug delivery system (SEDDS): future aspects. International journal of pharmacy and pharmaceutical sciences, 2 (4), 713.
   Google Scholar
• Leveque, D., Carvalho, M.C.M., and Maloisel, F., 2007. Clinical pharmacokinetics of bortezomib. In vivo, 21 (2), 273–278.
   PubMed Web of Science ®Google Scholar
• Li, S.-D. and Huang, L., 2008. Pharmacokinetics and biodistribution of nanoparticles. Molecular pharmaceutics, 5 (4), 496–504.
   PubMed Web of Science ®Google Scholar
• Liu, D. and Auguste, D.T.J., 2015. Cancer targeted therapeutics: from molecules to drug delivery vehicles. Journal of controlled release: official journal of the controlled release society, 219, 632–643.
   PubMed Web of Science ®Google Scholar
• Lub, S., et al., 2016. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget, 7 (6), 6521–6537.
   PubMedGoogle Scholar
• Mahmoudian, M., et al., 2020. Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system. Pharmaceutical development and technology, 25 (3), 351–358.
   PubMed Web of Science ®Google Scholar
• Mahmoudian, M., Valizadeh, H., and Zakeri-Milani, P., 2018. Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation. Drug development and industrial pharmacy, 44 (10), 1598–1605.
   PubMed Web of Science ®Google Scholar
• Manasanch, E.E. and Orlowski, R.Z., 2017. Proteasome inhibitors in cancer therapy. Nature reviews. Clinical oncology, 14 (7), 417–433.
   PubMed Web of Science ®Google Scholar
• Manjunath, K., Reddy, J.S., and Venkateswarlu, V., 2005. Solid lipid nanoparticles as drug delivery systems. Methods and findings in experimental and clinical pharmacology, 27 (2), 127–144.
   PubMed Web of Science ®Google Scholar
• Mistry, R.B. and Sheth, N.S., 2011. A review: self emulsifying drug delivery system. International journal of pharmacy and pharmaceutical sciences, 3 (2), 23–28.
   Google Scholar
• Mohan, M., Matin, A., and Davies, F.E., 2017. Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer management and research, 9, 51–63.
   PubMed Web of Science ®Google Scholar
• Moreau, P., et al., 2011. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The lancet oncology, 12 (5), 431–440.
   PubMed Web of Science ®Google Scholar
• Nix, D., et al., 2001. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Paper presented at the American society of clinical oncology.
   Google Scholar
• Olbrich, C., Kayser, O., and Müller, R.H., 2002. Enzymatic degradation of Dynasan 114 SLN–effect of surfactants and particle size. Journal of nanoparticle research, 4 (1–2), 121–129.
   Web of Science ®Google Scholar
• Petschauer, J.S., et al., 2015. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. Nanomedicine, 10 (3), 447–463.
   PubMed Web of Science ®Google Scholar
• Ping Dou, Q.A. and Zonder, J., 2014. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Current cancer drug targets, 14 (6), 517–536.
   PubMed Web of Science ®Google Scholar
• Pouton, C.W. and Porter, C.J., 2008. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Advanced drug delivery reviews, 60 (6), 625–637.
   PubMed Web of Science ®Google Scholar
• Raza, K., et al., 2017. Pharmacokinetics and biodistribution of the nanoparticles. In: Advances in nanomedicine for the delivery of therapeutic nucleic acids. New York, NY: Elsevier, 165–186.
   Google Scholar
• Reece, D.E., et al., 2011. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer chemotherapy and pharmacology, 67 (1), 57–67.
   PubMed Web of Science ®Google Scholar
• Rodallec, A., et al., 2018. Pharmacokinetics variability: why nanoparticles are not just magic-bullets in oncology. Critical reviews in oncology/hematology, 129, 1–12.
   PubMed Web of Science ®Google Scholar
• Sangsen, Y., et al., 2017. Comparisons between a self‐microemulsifying system and lipid nanoparticles of oxyresveratrol on the physicochemical properties and Caco‐2 cell permeability. European journal of lipid science and technology, 119 (3), 1600053.
   Web of Science ®Google Scholar
• Shekhawat, P.B. and Pokharkar, V.B., 2017. Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta pharmaceutica sinica B, 7 (3), 260–280.
   PubMed Web of Science ®Google Scholar
• Shrestha, H., Bala, R., and Arora, S.J.J., 2014. Lipid-based drug delivery systems. Journal of pharmaceutics, 2014, 1–10.
   Google Scholar
• Sultana, S., et al., 2013. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review. Journal of drug targeting, 21 (2), 107–125.
   PubMed Web of Science ®Google Scholar
• Teicher, B.A. and Tomaszewski, J.E., 2015. Proteasome inhibitors. Biochemical pharmacology, 96 (1), 1–9.
   PubMed Web of Science ®Google Scholar
• Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nature reviews. Drug discovery, 4 (2), 145–160.
   PubMed Web of Science ®Google Scholar
• Vipul, P., et al., 2010. Self emulsifying drug delivery system: a conventional and alternative approach to improve oral bioavailability of lipophilic drugs. International journal of drug development and research, 2, 859.
   Google Scholar
• Voorhees, P.M., et al., 2003. The proteasome as a target for cancer therapy. Clinical cancer research, 9 (17), 6316–6325.
   PubMed Web of Science ®Google Scholar
• Wu, W.K.K., et al., 2010. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer letters, 293 (1), 15–22.
   PubMed Web of Science ®Google Scholar
• Yadav, N., Khatak, S., and Sara, U.S., 2013. Solid lipid nanoparticles – a review. International journal of applied pharmaceutics, 5 (2), 8–18.
   Google Scholar
• Yang, X., et al., 2016. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. Oncotarget, 7 (24), 36382–36394.
   PubMedGoogle Scholar
• Yuan, D., et al., 2019. Physiologically based pharmacokinetic modeling of nanoparticles. Journal of pharmaceutical sciences, 108 (1), 58–72.
   PubMed Web of Science ®Google Scholar
• Zuccari, G., et al., 2015. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. Journal of controlled release, 211, 44–52.
   PubMed Web of Science ®Google Scholar